Delayed COVID-19 Respiratory Failure in Patients with Lymphoma on Rituximab-based Chemoimmunotherapy

• COVID-19 can present with delayed onset of symptoms in patients with lymphoma receiving rituximab-based chemoimmunotherapy. • Despite delayed onset of symptoms with prolonged asymptomatic period, outcomes can be particularly severe, including respiratory failure, thrombotic complications, and deat...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffmann, Marc S., Ganguly, Siddhartha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910130/
https://www.ncbi.nlm.nih.gov/pubmed/33712408
http://dx.doi.org/10.1016/j.clml.2021.02.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910130/
https://www.ncbi.nlm.nih.gov/pubmed/33712408
http://dx.doi.org/10.1016/j.clml.2021.02.009

Ejemplares similares